Skip to main content
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2022 Aug 22.
Published in final edited form as: J Pediatr. 2021 Sep 2;240:66–71.e4. doi: 10.1016/j.jpeds.2021.08.075

Medication Use in the Neonatal Intensive Care Unit and Changes from 2010–2018

Ashley Stark 1, P Brian Smith 1,2, Christoph P Hornik 1,2, Kanecia O Zimmerman 1,2, Chi D Hornik 1, Sidart Pradeep 3, Reese H Clark 4, Daniel K Benjamin Jr 1,2, Matthew Laughon 5, Rachel G Greenberg 1,2
PMCID: PMC9394450  NIHMSID: NIHMS1812913  PMID: 34481808

Abstract

Objective:

To provide up-to-date medication prescribing patterns in United States NICUs and to examine trends in prescribing patterns over time.

Study design:

We performed a cohort study of 799,016 infants treated in NICUs managed by the Pediatrix Medical Group from 2010–2018. We used three different methods to report counts of medication: exposure, courses, and days of use. We defined the change in frequency of medication administration by absolute and relative change. We examined the FDA package insert for each medication to determine if a medication was labeled for use in infants and used Pubmed to search for pharmacokinetics (PK) studies.

Results:

The most prescribed medications included: ampicillin, gentamicin, caffeine citrate, poractant alpha, morphine, vancomycin, furosemide, fentanyl, midazolam, and acetaminophen. Of the top 50 medications used in infants with extremely low birth weights (ELBW), only 20 (40%) are FDA labeled for use in infants; of those that are not labeled for use in infants, 13/30 (43%) had at least 2 published pharmacokinetic (PK) studies. Medications with the greatest relative increase in use from 2010 to 2018 included: dexmedetomidine, clonidine, rocuronium, levetiracetam, atropine, and diazoxide. Medications with the greatest relative decrease in use included: tromethamine (THAM) acetate, pancuronium, chloral hydrate, imipenem+cilastatin, and amikacin.

Conclusion:

Trends of medication use in the NICU change substantially over time. It is imperative to identify changes in medication usage in the NICU to better inform further prospective studies.


The most commonly used medications in the neonatal intensive care unit (NICU) frequently change over time. Of great concern is that the majority of these medications are not labeled for use in infants, nor are they supported by robust clinical trial data, leaving many clinicians to rely on anecdotal or outdated information (13). Pharmacokinetics (PK) studies conducted in infants are difficult to perform, primarily due to issues with recruitment and obtaining consent, and required time and financial expense (1). Additionally, infants hospitalized in a NICU are more likely to meet exclusionary criteria in clinical trials for safety, dosing, and efficacy, as they often are born preterm with a greater likelihood of renal and/or hepatic dysfunction (4). Recent PK trials have begun to inform proper dosing on some medications, yet many of these drugs still have not undergone United States Food and Drug Administration (FDA) label changes, and NICUs have been slow to adopt such recommendations in dosing changes based on PK data alone (58).

Previous publications detailing trends in medication use in the NICU were described through 2010 (4, 9). However, medication use in the NICU changes frequently, secondary to evolving clinical trial data, FDA label changes, changes in disease treatment, concerns regarding medication safety, and medication shortages. It is important to recognize that changes in medication usage are not always a reflection of updated safety and efficacy data or on FDA approval. Clinicians must stay abreast with the most current data regarding medication use. Thus, the objectives of this study were to provide the most up-to-date prescribing patterns amongst NICUs; to identify trends in prescribing patterns over time, and to compare to previously published data.

Methods

We performed a cohort study including a total of 363 NICUs from the Pediatrix Medical Group from 2010 to 2018. The Pediatrix Medical Group manages a prospective database that collects information from daily progress notes written by clinicians, which is then de-identified and compliant with the Health Insurance Portability and Accountability Act of 1996. To facilitate comparison with previous reports, vitamins (except vitamin A), nutritional supplements, vaccines, eye drops, and topical medications were excluded (4, 9). This study was approved by the Duke Institutional Review Board with a waiver of informed consent.

Definitions

We used three different methods to report counts of medication usage. Exposure was defined as the number of unique medication names reported for each infant. Total medication courses was defined as the number of times a unique medication name was reported in the database. Days of use was defined as the total number of days each medication was administered throughout the entire database. Figure 1 (online only) shows example calculations for exposure, total medication courses, and days of use. Separate calculations were performed for extremely low birth weight (ELBW, <1000g birth weight) infants.

We examined the FDA package insert for each medication. A medication was deemed “labeled for use” if dosing recommendations that specifically mentioned infants were listed. If a medication was listed as labeled for use for infants of a specific month of age and older, it was not considered labeled for use within the context of our study. For example, if the package insert specifically stated “safety and effectiveness of medication X have been approved in pediatric patients age 2 months and older,” it was not considered labeled for use for our population. PK studies were identified through PubMed search of keywords including the drug name and “pharmacokinetics”.

Statistical Analysis

We described the change in frequency of medication administration between 2010 and 2018 by absolute and relative change. We calculated the relative increase in medication use for medications with greater than 1/1,000 exposures in 2018 and the relative decrease in medication use for medications with greater than 1/1000 exposures in 2010. Calculations were repeated separately for infants with ELBW. Analyses were conducted using Stata 16.1 (College Station, TX).

Results

Our study included 799,016 infants, of which 43,102 (5%) were born with ELBW (Table 1, online). The median gestational age (GA) was 36 weeks (25th-75th percentile: 34–39 weeks) and median birth weight was 2640 g (25th-75th percentile: 1950– 3301 g). The median length of hospitalization was 9 days (25th-75th percentile: 4–20 days) with a 1.8% mortality.

We identified 2,575,536 unique medication courses for 276 medications, of which 631,144 (25%) of those courses were unique to infants with ELBW. The median number of medication courses per infant was 2 (25th-75th percentile: 0–3), and the number of unique medications per infant was 2 (25th-75th percentile: 0–3). For infants with ELBW specifically, the median number of medication courses was 11 (25th-75th percentile: 6–19), and the number of unique medications per infant was 9 (25th-75th percentile: 5–14).

The 10 most common medications by exposure for the entire cohort included: ampicillin, gentamicin, caffeine citrate, poractant alfa, morphine, vancomycin, furosemide, fentanyl, midazolam, and acetaminophen (Table 2). The 10 most common medications by exposure for infants with ELBW included: gentamicin, ampicillin, caffeine citrate, vancomycin, poractant alfa, furosemide, dopamine, fluconazole, fentanyl, and indomethacin (Table 3). Of the top 50 medications used in infants with ELBW from 2010 to 2018, only 20 (40%) were FDA approved. Of those medications that did not have FDA approval, 13/30 (43%) had at least 2 published PK studies. Of the 14 medications to which >20% of infants with ELBW were exposed, only 50% were FDA approved. Ninety-four percent of infants with ELBW were exposed to a medication that did not have FDA approval.

Table 2:

Medications Most Commonly Used in the NICU Ranked by Exposure

Rank Medication Exposurea Coursesa Days of Usea
1 Ampicillin 582 602 2266
2 Gentamicin 579 649 2452
3 Caffeine citrate 153 191 4221
4 Poractant alfa 89 100 100
5 Morphine 68 82 814
6 Vancomycin 61 93 502
7 Furosemide 58 118 389
8 Fentanyl 56 69 453
9 Midazolam 47 55 421
10 Acetaminophen 42 49 274
11 Dopamine 40 48 164
12 Calfactant 34 40 39
13 Beractant 30 34 34
14 Phenobarbital 27 34 218
15 Fluconazole 27 31 411
16 Erythromycin 26 27 78
17 Hydrocortisone 23 30 241
18 Indomethacin 22 28 66
19 Lorazepam 22 25 262
20 Cefotaxime 22 25 138
21 Albuterol 19 24 366
22 Ranitidine 18 21 144
23 Acyclovir 17 18 75
24 Dexamethasone 16 23 141
25 Epoietin alpha 14 18 296
26 Nitric oxide 14 15 86
27 Tobramycin 13 18 93
28 Simethicone 12 13 103
29 Piperacillin-tazobactam 12 16 96
30 Epinephrine 12 13 18
31 Nystatin oral 11 12 97
32 Alprostadil 11 11 20
33 Ursodeoxycholic acid 10 12 178
34 Cefazolin 10 12 36
35 Budesonide 10 12 222
36 Dobutamine 10 10 28
37 Chlorothiazide 10 12 157
38 Clindamycin 9 11 62
39 Insulin 9 11 33
40 Metronidazole 9 11 69
41 Lansoprazole 9 10 55
42 Vecuronium 9 10 29
43 Nafcillin 8 10 49
44 Spironolactone 8 10 136
45 Meropenem 8 10 80
46 Palivizumab 8 8 8
47 Amoxicillin 8 8 43
48 Methadone 8 9 122
49 Ceftazidime 8 9 56
50 Cefepime 7 9 56
51 Clotrimazole 7 7 39
52 Fluticasone 6 7 113
53 Phenylephrine 6 7 24
54 Oxacillin 6 7 34
55 Ibuprofen 6 8 23
56 Vitamin-A 6 6 135
57 Epinephrine - racemic 5 6 16
58 Famotidine 5 6 49
59 Penicillin G 5 5 39
60 Levothyroxine 4 5 68
61 Cholestyramine 4 4 27
62 Milrinone 4 4 21
63 Metoclopromide 4 5 40
64 Propranolol 4 4 13
65 Levetiracetam 4 4 15
66 Clonidine 4 4 79
67 Omeprazole 4 4 25
68 Prednisone 4 5 44
69 Aminophylline 4 4 40
70 Amikacin 3 4 21
71 Amphotericin B deoxycholate 3 3 26
72 Hyaluronidase 3 3 3
73 Hydrochlorothiazide 3 3 44
74 Naloxone 3 3 3
75 Beclomethasone 3 3 47
76 Sildenafil 3 3 30
77 Digoxin 3 3 11
78 Filgrastim 2 3 7
79 Aluminum/Magnesium Hydroxide 2 2 14
80 Cephalexin 2 2 11
81 Ceftriaxone 2 2 5
82 Dornase Alpha 2 3 18
83 Zidovudine 2 2 12
84 Adenosine 2 2 3
85 Sucralfate 2 2 13
86 Cefoxitin 2 2 5
87 Bumetanide 2 2 10
88 Azithromycin 2 2 10
89 Acetazolamide 2 3 14
90 Dexmedetomidine 2 2 16
91 Atropine 2 2 2
92 Heparin 2 2 14
93 Chloral hydrate 1 2 7
94 Pentobarbital 1 2 13
95 Linezolid 1 2 12
96 Rifampin 1 1 12
97 Hydralazine 1 1 14
98 Captopril 1 1 9
99 Diazoxide 1 1 7
100 Enalapril 1 1 8
a

Units for exposure, courses, and days of use, per 1000 infants.

Table 3:

Medications Most Commonly Used in the NICU for ELBW Infants Ranked by Exposure

Rank Medication Exposurea Coursesa Days of Usea FDA Label for Use
1 Gentamicin 897 1613 7392 Yes
2 Ampicillin 872 1032 4466 Yes
3 Caffeine citrate 866 1135 38051 Yes
4 Vancomycin 480 905 4987 Yes
5 Poractant alfa 460 556 562 Yes
6 Furosemide 455 1238 4366 No
7 Dopamine 351 488 1748 No
8 Fluconazole 321 380 5654 No
9 Fentanyl 302 439 4329 No
10 Indomethacin 297 381 900 Yes
11 Hydrocortisone 237 342 3252 No
12 Morphine 222 324 3426 No
13 Midazolam 209 292 3656 Yes
14 Albuterol 203 282 5170 No
15 Calfactant 188 240 235 Yes
16 Dexamethasone 182 292 2051 No
17 Acetaminophen 166 214 1102 Yes
18 Beractant 159 189 192 Yes
19 Budesonide 131 159 3390 No
20 Insulin 127 162 505 No
21 Cefotaxime 126 167 1023 Yes
22 Chlorothiazide 113 152 2203 No
23 Lorazepam 108 141 2448 No
24 Epinephrine 105 117 161 No
25 Phenobarbital 100 133 1808 No
26 Spironolactone 99 130 1938 No
27 Epoietin alpha 98 134 2799 No
28 Piperacillin-tazobactam 96 135 848 No
29 Ursodeoxycholic acid 94 121 2421 No
30 Ranitidine 88 112 991 No
31 Tobramycin 85 149 912 Yes
32 Dobutamine 80 92 245 No
33 Meropenem 78 107 857 Yes
34 Nitric oxide 77 92 729 No
35 Nafcillin 75 102 522 No
36 Ceftazidime 74 97 610 Yes
37 Fluticasone 73 93 1635 No
38 Metronidazole 70 88 538 No
39 Vitamin-A 69 71 1788 No
40 Ibuprofen 67 95 281 Yes
41 Clindamycin 64 74 443 Yes
42 Cefepime 63 81 545 No
43 Cefazolin 61 72 224 No
44 Erythromycin 57 65 531 Yes
45 Vecuronium 55 74 232 No
46 Oxacillin 51 68 335 Yes
47 Lansoprazole 47 53 446 No
48 Levothyroxine 46 50 1063 Yes
49 Nystatin oral 44 48 678 Yes
50 Prednisone 43 58 601 No
a

Units for exposure, courses, and days of use, per 1000 infants.

NICU = neonatal intensive care unit; ELBW = extremely low birthweight FDA = Federal Drug Administration

Medication Increases between 2010 and 2018

The medications with the greatest absolute increase based on total exposures between 2010 and 2018 included: poractant alfa, morphine, erythromycin, glucose gel, simethicone, budesonide, clonidine, acetaminophen, and dexmedetomidine (Table 4). Notably, poractant alfa showed the greatest absolute increase in both the entirety of our cohort as well as the ELBW cohort (Table 5, online). The medications with the greatest relative increase based on total exposures between 2010 and 2018 included: dexmedetomidine, clonidine, rocuronium, levetiracetam, atropine, diazoxide, vasopressin/desmopressin, glycopyrrolate, simethicone, and glucagon (Table 6). Dexmedetomidine showed the greatest relative increase in both cohorts (Table 7, online). Four of the top 20 (20%) medications that showed the greatest absolute increase from 2010 to 2018 were FDA approved, whereas 4/20 (20%) of medications that showed the greatest relative increase during this same time were FDA approved.

Table 4:

Greatest Absolute Increase in Exposure Between 2010 and 2018

Rank Medication Exposure Increasea Exposure in 2010a Exposure in 2018a FDA Label for Use
1 Poractant alfa 45.0 63.4 108.4 Yes
2 Morphine 19.7 53.7 73.4 No
3 Erythromycin 9.8 24.1 33.9 Yes
4 Glucose gel 8.8 0.0 8.8 No
5 Simethicone 8.4 7.5 15.9 No
6 Budesonide 6.8 7.5 14.3 No
7 Clonidine 6.3 0.4 6.7 No
8 Acetaminophen 5.3 40.9 46.2 Yes
9 Dexmedetomidine 5.0 0.1 5.1 No
10 Fluconazole 4.7 20.8 25.5 No
11 Levetiracetam 4.7 1.7 6.4 No
12 Hydrocortisone 4.5 21.6 26.1 No
13 Cefepime 4.1 7.9 12.0 No
14 Cefazolin 2.9 8.4 11.3 No
15 Cholestyramine 1.9 3.4 5.3 No
16 Atropine 1.7 0.9 2.6 No
17 Rocuronium 1.4 0.2 1.6 No
18 Penicillin G 1.3 4.7 6.0 No
19 Ceftriaxone 1.2 1.3 2.5 Yes
20 Dexamethasone 1.1 15.7 16.8 No
a

Per 1000 infants

FDA = Federal Drug Administration

Table 6:

Greatest Relative Increase in Exposure Between 2010 and 2018

Rank Medication % Change Exposure (2010)a Exposure (2018)a FDA Label for Use
1 Dexmedetomidine 5000 0.1 5.1 No
2 Clonidine 1575 0.4 6.7 No
3 Rocuronium 700 0.2 1.6 No
4 Levetiracetam 276 1.7 6.4 No
5 Atropine 189 0.9 2.6 No
6 Diazoxide 150 0.6 1.5 Yes
7 Vasopressin/Desmopressin 140 0.5 1.2 No
8 Glycopyrrolate 120 0.5 1.1 No
9 Simethicone 112 7.5 15.9 No
10 Glucagon 100 0.5 1.0 No
11 Ceftriaxone 92 1.3 2.5 Yes
12 Budesonide 91 7.5 14.3 No
13 Sucralfate 71 1.4 2.4 No
14 Poractant alfa 71 63.4 108.4 Yes
15 Ampicillin-sulbactam 57 0.7 1.1 No
16 Cholestyramine 56 3.4 5.3 No
17 Cefepime 52 7.9 12.0 No
18 Ganciclovir 43 0.7 1.0 No
19 Erythromycin 41 24.1 33.9 Yes
20 Magnesium sulfate 38 0.8 1.1 No
a

Per 1,000 infants

FDA = Federal Drug Administration

Medication Decreases between 2010 and 2018

The medications with the greatest absolute decrease based on total exposures between 2010 and 2018 included: ampicillin, gentamicin, beractant, vancomycin, calfactant, furosemide, cefotaxime, ranitidine, fentanyl, and midazolam (Table 8, online). Medications also showing the greatest absolute decrease based on total exposures in infants with ELBW included: beractant, vancomycin, calfactant, cefotaxime, ranitidine, and ampicillin (Table 9, online). Notably, although ampicillin and gentamicin were ranked number 1 and 2, respectively, in medication exposure and ranked number 2 and 1 in medication exposure for infants with ELBW, they were also the top two medications that showed the greatest absolute decrease. The medications with the greatest relative decrease based on total exposures between 2010 and 2018 included: tromethamine (THAM) acetate, pancuronium, chloral hydrate, imipenem+cilastatin, amikacin, metoclopramide, pentobarbital, beractant, vitamin A and diazepam (Table 10, online). Medications with the greatest relative decrease in infants with ELBW between 2010 and 2018 included: ticarcillin/ticarcillin+clavulanate, cimetidine, antacids, ammonium chloride, and flucytosine (Table 11, online).

Discussion

The medications used in the NICU change frequently over time. Notably, half of these medications (ampicillin, gentamicin, caffeine citrate, furosemide, and vancomycin) have remained in the top 10 most common medications since the initial study starting in 1996, whereas 7 (gentamicin, ampicillin, caffeine citrate, furosemide, vancomycin, fentanyl, and midazolam) have remained since the follow-up study starting in 2005 (4, 9). Of the 10 most common medications by exposure for infants with ELBW (Table 3), 8 have remained in the top 10 since 2005 (4).

Of concern is the continued use of medications that are not labeled for use in infants (4, 8, 9). Our study identified that only 40% of medications used in infants with ELBW are FDA approved, slightly improved from 2005–2010 when 35% of medications were approved in this population. In the current study, 94% of infants with ELBW were exposed to a medication that was not labeled for use in infants (4). However, our definition of labeled for use was necessarily broad and unable to account for differences in approval for specific indications or of specific gestational ages but not others; thus, the percentage of FDA-approved drugs in the ELBW population is likely lower than our estimate. Nearly all infants admitted to the NICU receive at least one medication that is unlicensed or used off label, and it is estimated that >70% of infants in the NICU are exposed to drug-drug interactions (1, 3, 10). Off-label usage exposes infants to many risks including over-dosing and thus increasing the risk of adverse reactions or under-dosing, thus leading to ineffective treatment (11). Clinicians may be unaware that they are prescribing a medication that does not have FDA labeling. Without such labeling, clinicians may rely on reference guidelines based largely on adult and adolescent data that often do not account for variations in medication absorption, metabolism, and excretion of infants, or references databases that may not use the most up to date PK trial data (5, 8, 1215). The FDA Modernization Act of 1997, which was extended in 2002 as the Best Pharmaceuticals for Children Act, attempted to bridge this gap by creating incentives such as exclusive marketing and patent extension for pharmaceutical companies to test medications in children; the 2003 Pediatric Research Equity Act requires new drug applications to submit dosing data in pediatric populations (15, 16). However, the process can be costly and time-consuming, and often approval for a new indication does not offset the cost of obtaining said approval, thus leaving pharmaceutical companies with little financial incentive to pursue such an endeavor (16). Lack of FDA approval for the majority of the most common medications used in infants is a public health concern.

Previous research has demonstrated publishing of PK studies has the potential to increase adherence to PK-based dosing in the neonatal population (8). Dexmedetomidine, a medication previously not within the top 100 medications used from 2005 to 2010, ranked as the medication with the greatest relative increase (9th greatest absolute increase) and the 90th most common medication used in the NICU from 2010 to 2018 (4). Although not currently labeled for use in infants, recently published PK studies support a low adverse effect profile, particularly with infants undergoing cardiopulmonary bypass (1719). It is likely, given its supporting PK studies and advantageous safety profile in term infants, that dexmedetomidine will continue to be a common medication used in the NICU. However, there remains a lack of robust safety and efficacy data for infants exposed to dexmedetomidine, particularly those with ELBW.

Despite the lack of supporting data for many medications used in the NICU, well-designed studies of the different brands of medications such as surfactant are likely responsible for the changes in usage (2023). Poractant alfa showed the greatest absolute increase of medications used in the NICU and was ranked as the fourth most common medication from 2010 to 2018. It was ranked as the fifth most common medication and the greatest absolute increase in infants with ELBW. A recent prospective trial of surfactants showed repeated dosing, increased FiO2 requirements, and decreased PaO2 values in the calfactant group compared with the poractant alfa and beractant groups (22). However, no differences were seen in prevention of combined outcomes such as air leak syndromes, including pneumothorax and pulmonary interstitial emphysema, BPD and death, and death (23). It is possible that although poractant alfa has not been shown to have a long-term benefit over calfactant and beractant, clinicians prefer its use due to its more immediate and tangible effects.

Medication usage trends often follow trends in diseases of the neonate. Neonatal opioid withdrawal syndrome has become a rapidly increasing issue within NICUs nationally, with its incidence increasing more than five-fold from 2004 to 2014 in Medicaid-covered births and from 3.4 to 5.8 per 1000 hospital births from 2009 to 2012 (24, 25). Clonidine, a medication not noted in the previous study, is now one of the most commonly used drugs in the NICU (rank 66th) (4). Morphine also demonstrated an increase (second greatest absolute increase in medication use). Notably, neither morphine nor clonidine is FDA approved for use in infants. Although there is no consensus as to the best medication for neonatal opioid withdrawal syndrome following a failed non-pharmacotherapeutic intervention, there is concern for potential developmental harm with additional opiate exposure during the period of rapid brain development (26). Clonidine, as adjunctive therapy, has been shown to decrease the number of morphine doses and decrease the duration of treatment in term infants exposed to methadone or heroin with neonatal opioid withdrawal syndrome (27). A recent trial of monotherapy with clonidine versus morphine showed a decrease in treatment duration (39 versus 28 days, p=0.02), a decreased height of arousal and excitability during treatment, and no differences in cognitive, motor or language outcomes at one year of age (26).

The introduction of new research regarding the treatment of common neonatal problems similarly dictates medication usage in the NICU. Although gentamicin and ampicillin continued to hold the ranking for the first and second most commonly used medications in the NICU both from 2005 to 2010 and from 2010 to 2018 (ranked first and second, respectively, for the top medications used in infants with ELBW), both were listed as the two top medications that experienced the greatest absolute decrease from 2010 to 2018 (4). This is likely related to the publication of a risk-stratifying algorithm for early-onset sepsis in infants of >35 weeks GA in which empiric antibiotic administration within the first 24 hours after birth with no statistically significant differences seen in culture-confirmed early-onset sepsis or readmission (2831). Quality improvement initiatives at additional sites have already demonstrated a decrease in antibiotic exposure after implementation of the algorithm (32). Implementation of this risk-stratification to hospitals outside of the initial study group may be responsible for the overall decrease seen in the usage of ampicillin and gentamicin.

Although the introduction of new research can dictate medication trends in the NICU, some medications are more frequently used without any supporting data or data with mixed results. For example, simethicone, a medication that has very little data supporting its use, particularly in the neonatal population, was ranked as the 5th greatest absolute increase and 9th greatest relative increase from 2010 to 2018 and 28th overall for most used medications. However, multiple studies have shown that it is no more effective than a placebo and its use in premature infants is scarce (33, 34). Comparatively, early inhaled budesonide usage in extremely premature infants shows promise in decreasing the incidence of bronchopulmonary dysplasia, however these infants showed increased overall mortality (35, 36). Nonetheless, budesonide usage increased amongst both the entirety of our cohort and infants with ELBW.

Strengths of this study include a large, representative cohort spanning many NICUs across the country as well as daily documentation of medication usage, but there were also limitations. The Pediatrix Medical Group is a prospectively collected database that is not subject to independent monitoring. Additionally, the database does not include the indications for medication usage, which may provide more in-depth information as to why certain medications experience an increase or decrease in usage. Lastly, our method of counting and threshold of >1/1000 exposures may have led us to rank more highly large relative increases or decreases in the usage of medications that are rarely used overall.

We identified the most commonly used medications in the NICU, particularly amongst infants with ELBW, how medication usage has changed over time, and how such changes may be related to ongoing medication research. Safe prescribing of medications, as directed by guidelines, PK, safety and efficacy studies, and FDA label changes, should remain a priority focus within neonatal research.

Supplementary Material

Figure 2
Figure 1. Figure 1, online: Flow diagram Illustrating Process of Calculating Exposure, Total Medication Courses and Days of Use.

In this example, infants A, B and C were all prescribed ampicillin, which was prescribed to two infants once (infants A and B) and to one infant (infant C) twice for a duration of 2 days each. The exposure would be reported as 1 + 1 + 1 = 3, course = 1 + 1+ 2 = 4 and days of use = (1 × 2) + (1 × 2) + (2 × 2) = 8. Infant B was prescribed gentamicin once for 2 days; thus, the exposure would be reported as 1, course as 1, and days of use = (1 × 2) = 2.

Supplemental Table 1
Supplemental Table 5
Supplemental Table 7
Supplemental Table 8
Supplemental Table 9
Supplemental Table 10
Supplemental Table 11

Footnotes

Conflicts of Interest Disclosures

Dr. Smith has received support from SPARC Pharma, Nestle, and UCB and receives support from NIH U2COD023375

Dr. CP Hornik has received support from Anavex Pharmaceuticals, Purdue Pharma, and Cytokinetics

Dr. CD Hornik receives support for research from the NICHD funded Pediatric Trials Network (HHSN2752010000031).

Dr. Laughon has received support from Cempra, Medipost, and United Therapeutics.

Dr. Benjamin has received support from Allergan, Inc., Melinta Therapeutics, and Sun Pharma Advanced Research Company and receives support from K24 HL143283.

References:

  • 1.Conroy S, McIntyre J. The use of unlicensed and off-label medicines in the neonate. Seminars in fetal & neonatal medicine. 2005;10(2):115–22. [DOI] [PubMed] [Google Scholar]
  • 2.Bavdekar SB, Gogtay NJ. Unlicensed and off-label drug use in children. J Postgrad Med. 2005;51(4):249–52. [PubMed] [Google Scholar]
  • 3.de Souza AS Jr., Dos Santos DB, Rey LC, Medeiros MG, Vieira MG, Coelho HLL. Off-label use and harmful potential of drugs in a NICU in Brazil: A descriptive study. BMC pediatrics. 2016;16:13. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Hsieh EM, Hornik CP, Clark RH, Laughon MM, Benjamin DK Jr., Smith PB. Medication use in the neonatal intensive care unit. American Journal of Perinatology. 2014;31(9):811–22. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.O’Hara K, Wright IM, Schneider JJ, Jones AL, Martin JH. Pharmacokinetics in neonatal prescribing: evidence base, paradigms and the future. British journal of clinical pharmacology. 2015;80(6):1281–8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Smith PB, Cohen-Wolkowiez M, Castro LM, Poindexter B, Bidegain M, Weitkamp JH, et al. Population pharmacokinetics of meropenem in plasma and cerebrospinal fluid of infants with suspected or complicated intra-abdominal infections. Pediatr Infect Dis J. 2011;30(10):844–9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Piper L, Smith PB, Hornik CP, Cheifetz IM, Barrett JS, Moorthy G, et al. Fluconazole loading dose pharmacokinetics and safety in infants. Pediatr Infect Dis J. 2011;30(5):375–8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Stark A, Childers J, England M, Clark RH, Laughon M, Cohen-Wolkowiez M, et al. Dosing of Antimicrobials in the Neonatal Intensive Care Unit: Does Clinical Practice Reflect Pharmacokinetics-based Recommendations? Pediatr Infect Dis J. 2020;39(8):713–7. [DOI] [PubMed] [Google Scholar]
  • 9.Clark RH, Bloom Bt Fau - Spitzer AR, Spitzer Ar Fau - Gerstmann DR, Gerstmann DR. Reported medication use in the neonatal intensive care unit: data from a large national data set. (1098–4275 (Electronic; )). [DOI] [PubMed] [Google Scholar]
  • 10.Haline Tereza Costa RWDL, Tatiana Xavier da, Costa AGO, Rand Randall Martins. Drug-Drug Interactions in Neonatal Intensive Care: A Prospective Cohort Study. Pediatrics and Neonatology. 2020. [DOI] [PubMed] [Google Scholar]
  • 11.Ku LC, Smith PB. Dosing in neonates: special considerations in physiology and trial design. (1530–0447 (Electronic; )). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Johnson JK, Laughon MM. Antimicrobial Agent Dosing in Infants. Clin Ther. 2016;38(9):1948–60. [DOI] [PubMed] [Google Scholar]
  • 13.Hughes H, Kahl L. The Harriet Lane handbook : a manual for pediatric house officers. 2018. [Google Scholar]
  • 14.Kimberlin MDFDW, Long MDFSS, Brady MT, Jackson MA. Red Book 2018–2021 : Report of the Committee on Infectious Diseases. 2018.
  • 15.Field MJ, Boat Thomas F. Committee on Pediatric Studies Conducted Under the Best Pharmaceuticals for Children Act (BPCA) and the Pediatric Research Equity Act (PREA). Washington (DC): National Academies Press (US); 2012. [PubMed] [Google Scholar]
  • 16.Wittich CM, Burkle CM, Lanier WL. Ten common questions (and their answers) about off-label drug use. Mayo Clin Proc. 2012;87(10):982–90. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Zuppa AF, Nicolson SC, Wilder NS, Ibla JC, Gottlieb EA, Burns KM, et al. Results of a phase 1 multicentre investigation of dexmedetomidine bolus and infusion in corrective infant cardiac surgery. Br J Anaesth. 2019;123(6):839–52. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Zimmerman KO, Wu H, Laughon M, Greenberg RG, Walczak R, Schulman SR, et al. Dexmedetomidine Pharmacokinetics and a New Dosing Paradigm in Infants Supported With Cardiopulmonary Bypass. Anesth Analg. 2019;129(6):1519–28. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Greenberg RG, Wu H, Laughon M, Capparelli E, Rowe S, Zimmerman KO, et al. Population Pharmacokinetics of Dexmedetomidine in Infants. J Clin Pharmacol. 2017;57(9):1174–82. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Singh N, Hawley KL, Viswanathan K. Efficacy of porcine versus bovine surfactants for preterm newborns with respiratory distress syndrome: systematic review and meta-analysis. Pediatrics. 2011;128(6):e1588–95. [DOI] [PubMed] [Google Scholar]
  • 21.Sánchez Luna M, Bacher P, Unnebrink K, Martinez-Tristani M, Ramos Navarro C. Beractant and poractant alfa in premature neonates with respiratory distress syndrome: a systematic review of real-world evidence studies and randomized controlled trials. J Perinatol. 2020;40(8):1121–34. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Dilli DA-O, Çakmakçı EA-O, Akduman HA-O, Oktem AA-O, Aydoğan SA-O, Çitli RA-O, et al. Comparison of three natural surfactants according to lung ultrasonography scores in newborns with respiratory distress syndrome. (1476–4954 (Electronic; )). [DOI] [PubMed] [Google Scholar]
  • 23.Trembath A, Hornik CP, Clark R, Smith PB, Daniels J, Laughon M. Comparative effectiveness of surfactant preparations in premature infants. J Pediatr. 2013;163(4):955–60.e1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Winkelman TNA, Villapiano N, Kozhimannil KB, Davis MM, Patrick SW. Incidence and Costs of Neonatal Abstinence Syndrome Among Infants With Medicaid: 2004–2014. Pediatrics. 2018;141(4). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Patrick SW, Davis MM, Lehmann CU, Cooper WO. Increasing incidence and geographic distribution of neonatal abstinence syndrome: United States 2009 to 2012. J Perinatol. 2015;35(8):650–5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Bada HS, Sithisarn T, Gibson J, Garlitz K, Caldwell R, Capilouto G, et al. Morphine versus clonidine for neonatal abstinence syndrome. Pediatrics. 2015;135(2):e383–91. [DOI] [PubMed] [Google Scholar]
  • 27.Agthe AG, Kim GR, Mathias KB, Hendrix CW, Chavez-Valdez R, Jansson L, et al. Clonidine as an adjunct therapy to opioids for neonatal abstinence syndrome: a randomized, controlled trial. Pediatrics. 2009;123(5):e849–56. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Kuzniewicz MW, Puopolo KM, Fischer A, Walsh EM, Li S, Newman TB, et al. A Quantitative, Risk-Based Approach to the Management of Neonatal Early-Onset Sepsis. JAMA Pediatr. 2017;171(4):365–71. [DOI] [PubMed] [Google Scholar]
  • 29.Escobar GJ, Puopolo KM, Wi S, Turk BJ, Kuzniewicz MW, Walsh EM, et al. Stratification of risk of early-onset sepsis in newborns ≥ 34 weeks’ gestation. Pediatrics. 2014;133(1):30–6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Puopolo KM, Draper D, Wi S, Newman TB, Zupancic J, Lieberman E, et al. Estimating the probability of neonatal early-onset infection on the basis of maternal risk factors. Pediatrics. 2011;128(5):e1155–63. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Kuzniewicz MW, Walsh EM, Li S, Fischer A, Escobar GJ. Development and Implementation of an Early-Onset Sepsis Calculator to Guide Antibiotic Management in Late Preterm and Term Neonates. Jt Comm J Qual Patient Saf. 2016;42(5):232–9. [DOI] [PubMed] [Google Scholar]
  • 32.Zayek M, Bhat J, Bonner K, Blake M, Peevy K, Jha OP, et al. Implementation of a Modified Neonatal Early-onset Sepsis Calculator in Well-baby Nursery: a Quality Improvement Study. Pediatr Qual Saf. 2020;5(4):e330. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Metcalf TJ, Irons TG, Sher LD, Young PC. Simethicone in the treatment of infant colic: a randomized, placebo-controlled, multicenter trial. Pediatrics. 1994;94(1):29–34. [PubMed] [Google Scholar]
  • 34.Sarasu JM, Narang M, Shah D. Infantile Colic: An Update. Indian Pediatr. 2018;55(11):979–87. [PubMed] [Google Scholar]
  • 35.Bassler D, Plavka R, Shinwell ES, Hallman M, Jarreau PH, Carnielli V, et al. Early Inhaled Budesonide for the Prevention of Bronchopulmonary Dysplasia. N Engl J Med. 2015;373(16):1497–506. [DOI] [PubMed] [Google Scholar]
  • 36.Filippone M, Nardo D, Bonadies L, Salvadori S, Baraldi E. Update on Postnatal Corticosteroids to Prevent or Treat Bronchopulmonary Dysplasia. Am J Perinatol. 2019;36(S 02):S58–s62. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Figure 2
Figure 1. Figure 1, online: Flow diagram Illustrating Process of Calculating Exposure, Total Medication Courses and Days of Use.

In this example, infants A, B and C were all prescribed ampicillin, which was prescribed to two infants once (infants A and B) and to one infant (infant C) twice for a duration of 2 days each. The exposure would be reported as 1 + 1 + 1 = 3, course = 1 + 1+ 2 = 4 and days of use = (1 × 2) + (1 × 2) + (2 × 2) = 8. Infant B was prescribed gentamicin once for 2 days; thus, the exposure would be reported as 1, course as 1, and days of use = (1 × 2) = 2.

Supplemental Table 1
Supplemental Table 5
Supplemental Table 7
Supplemental Table 8
Supplemental Table 9
Supplemental Table 10
Supplemental Table 11

RESOURCES